ResearcherErasmus MCActive in the last 2 years
Hassana el Haddaoui
Matched on ORCID iD 0000-0002-1789-6750; OpenAlex author ID A5006707635. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 3
- Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. First author DOI 10.1158/1078-0432.ccr-23-4085↗
- Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3. Co-author PMID 37424830↗
- Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancr… Co-author DOI 10.3390/cancers14061377↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dana A. M. Mustafa · 3 shared papers, 2022–2024 · strength 0.57
- Paper Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. DOI 10.1158/1078-0432.ccr-23-4085↗
- Paper Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3. PMID 37424830↗
- Paper Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with… DOI 10.3390/cancers14061377↗
- Casper H.J. van Eijck · 3 shared papers, 2022–2024 · strength 0.57
- Paper Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. DOI 10.1158/1078-0432.ccr-23-4085↗
- Paper Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3. PMID 37424830↗
- Paper Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with… DOI 10.3390/cancers14061377↗
- Casper W.F. van Eijck · 2 shared papers, 2023–2024 · strength 0.41
- Marcella Willemsen · 1 shared paper, 2024 · strength 0.22
- Songul Kucukcelebi · 1 shared paper, 2024 · strength 0.22
- Leo J. Hofland · 1 shared paper, 2023 · strength 0.19
- Michail Doukas · 1 shared paper, 2023 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.